New Study Shows Rapid EGFR testing with Idylla!
Products are for professional/laboratory use only.
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
24Mar
News
02Feb
Biocartis Launches Liquid Biopsy Idylla™ ctEGFR Mutation Assay (RUO)
Products are for professional/laboratory use only.
Biocartis is pleased to announce the launch of the Idylla™ ctEGFR Mutation Assay (RUO1). This assay is the liquid biopsy version of the solid biopsy Idylla™ EGFR Mutation Test (CE-IVD).
02Feb
Biocartis announces CE-IVD marking of its Idylla™ MSI Test
Products are for professional/laboratory use only.
Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the CE-IVD marking of its fully automated Idylla™ MSI Test which allows for fast and accurate information on a patient’s MSI status directly from a single sample of FFPE[1] colorectal cancer tumor tissue. This CE-IVD launch is a key addition to Biocartis’ colorectal cancer (CRC) Idylla™ test menu as MSI detection is currently recommended for all patients with CRC[2].
03Feb
Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
Products are for professional/laboratory use only.
Press Release: Mechelen, Belgium, 27 June 2018
03Feb
Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
Products are for professional/laboratory use only.
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).
03Feb
Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests
Products are for professional/laboratory use only.
A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).
03Feb
Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only)
Products are for professional/laboratory use only.
Being the third¹ liquid biopsy test for Biocartis, the Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
03Feb
Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Products are for professional/laboratory use only.
Biocartis is pleased to announce the publication of an important study [1] by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.
03Feb
Discover Idylla Explore – offering insight into your molecular data
Products are for professional/laboratory use only.
Get connected and enjoy the advantages of Idylla Explore, a web-based application that allows you to analyze your data by providing: